ReviewCurrent heart failure reports2016
The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction.
Review in Current heart failure reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Systematic review and meta-analysis of nitrates/nitrites in patients with heart failure or pulmonary hypertension.European journal of medical research · 2025Pooled it
- The effect of dietary nitrate on exercise capacity in chronic kidney disease: a randomized controlled pilot study.Nitric oxide : biology and chemistry · 2021Trial
- Effect of organic and inorganic nitrates on cerebrovascular pulsatile power transmission in patients with heart failure and preserved ejection fraction.Physiological measurement · 2018Trial
- Effects of organic and inorganic nitrate on aortic and carotid haemodynamics in heart failure with preserved ejection fraction.European journal of heart failure · 2017Trial
- The acute effects of exercise intensity and inorganic nitrate supplementation on the Buckberg ratio in postmenopausal females.Experimental physiology · 2026Article
- Gas entrapping materials for damage control.Advanced drug delivery reviews · 2026Review
- Dysregulated ProteinCirculation research · 2025Article
- Article
- Combination Sodium Nitrite and Hydralazine Therapy Attenuates Heart Failure With Preserved Ejection Fraction Severity in a "2-Hit" Murine Model.Journal of the American Heart Association · 2023Article
- The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies.Aging and disease · 2023Article
- Systems Pharmacology-Based Strategy to Investigate Pharmacological Mechanisms of Total Flavonoids inInternational journal of molecular sciences · 2022Article
- VDAC2 as a novel target for heart failure: CaCell calcium · 2022Review
- The Cardiomyocyte in Heart Failure with Preserved Ejection Fraction-Victim of Its Environment?Cells · 2022Review
- Age and Sex Differences in Heart Failure With Preserved Ejection Fraction.Frontiers in aging · 2022Review
- Crossroads between Estrogen Loss, Obesity, and Heart Failure with Preserved Ejection Fraction.Arquivos brasileiros de cardiologia · 2021Review
- Development of heart failure with preserved ejection fraction in type 2 diabetic mice is ameliorated by preserving vascular function.Life sciences · 2021Article
- Arginine metabolism and nitric oxide turnover in the ZSF1 animal model for heart failure with preserved ejection fraction.Scientific reports · 2021Article
- Cellular and molecular pathobiology of heart failure with preserved ejection fraction.Nature reviews. Cardiology · 2021Review
- Mechanisms underlying the pathophysiology of heart failure with preserved ejection fraction: the tip of the iceberg.Heart failure reviews · 2021Review
- Effects of inorganic nitrate supplementation on cardiovascular function and exercise tolerance in heart failure.Journal of applied physiology (Bethesda, Md. : 1985) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The pathogenesis of exercise intolerance in patients with heart failure and preserved ejection fraction (HFpEF) is likely multifactorial. In addition to cardiac abnormalities (diastolic dysfunction, abnormal contractile reserve, chronotropic incompetence), several peripheral abnormalities are likely to be involved. These include abnormal pulsatile hemodynamics, abnormal arterial vasodilatory responses to exercise, and abnormal peripheral O2 delivery, extraction, and utilization. The nitrate-nitrite-NO pathway is emerging as a potential target to modify key physiologic abnormalities, including late systolic left ventricular (LV) load from arterial wave reflections (which has deleterious short- and long-term consequences for the LV), arterial vasodilatory reserve, muscle O2 delivery, and skeletal muscle mitochondrial function. In a recently completed randomized trial, the administration of a single dose of exogenous inorganic nitrate has been shown to exert various salutary arterial hemodynamic effects, ultimately leading to enhanced aerobic capacity in patients with HFpEF. These effects have the potential for both immediate improvements in exercise tolerance and for long-term "disease-modifying" effects. In this review, we provide an overview of key mechanistic contributors to exercise intolerance in HFpEF, and of the potential therapeutic role of drugs that target the nitrate-nitrite-NO pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.